Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$8M Sell
22,329
-6,760
-23% -$2.31M 1.31% 26
2026
Q1
$10.2M Buy
29,089
+1,271
+5% +$453K 1.92% 7
2025
Q4
$9.18M Buy
27,818
+1,877
+7% +$595K 1.81% 8
2025
Q3
$7.71M Buy
25,941
+1,669
+7% +$484K 1.65% 12
2025
Q2
$6.78M Buy
24,272
+5,132
+27% +$1.45M 1.65% 13
2025
Q1
$5.96M Buy
+19,140
New +$5.65M 1.56% 17
2021
Q4
Sell
-12,590
Closed -$2.68M 147
2021
Q3
$2.68M Buy
12,590
+2,318
+23% +$534K 1.22% 32
2021
Q2
$2.5M Buy
10,272
+1,429
+16% +$352K 1.22% 29
2021
Q1
$2.2M Buy
8,843
+819
+10% +$195K 1.32% 22
2020
Q4
$1.84M Buy
+8,024
New +$1.85M 1.34% 22

Other funds holding AMGN

Ellsworth Advisors's AMGN Position: Q2 2026 in Review

Ellsworth Advisors reduced its Amgen (AMGN) stake by 23% in Q2 2026, selling an estimated $2.31M and leaving 22,329 shares worth $8M. The position accounts for 1.31% of the portfolio, ranked #26.

Ellsworth Advisors first reported a position in AMGN in Q4 2020 and has held it in 10 quarters since. The position peaked at $10.2M in Q1 2026. 659 funds tracked by Wall St. Rank hold AMGN as of Q2 2026.

  • Ellsworth Advisors held 22,329 shares of Amgen worth $8M as of Q2 2026.
  • Ellsworth Advisors sold 6,760 Amgen shares in Q2 2026, an estimated $2.31M.
  • Amgen made up 1.31% of Ellsworth Advisors's portfolio in Q2 2026, its #26 holding.
  • Ellsworth Advisors first reported a position in Amgen in Q4 2020 and has held it in 10 quarters since.
  • Ellsworth Advisors's Amgen position peaked at $10.2M in Q1 2026.
  • 659 funds tracked by Wall St. Rank held Amgen as of Q2 2026.

Based on Ellsworth Advisors's 13F filing for Q2 2026, filed 16 Jul 2026.